Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Azacytidine Pre-Transplant for High Risk MDS
NCT00721214Phase 2Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Jul 2008
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Virginia Commonwealth University. Primary endpoints: Overall Survival of Allogeneic Transplant Recipients After Transplantation at 2 years and Event Free Survival for Allogeneic Transplant Recipients After Transplantation at 2 years. Started Jul 2008; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00721214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00721214.